Berberine Facilitates Extinction of Drug-Associated Behavior and Inhibits Reinstatement of Drug Seeking.
berberine
drug addiction
drug-associated memory
extinction
relapse
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
01
2020
accepted:
26
03
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
A high rate of relapse is a major clinical problem among drug-addicted individuals. Persistent traces of drug-associated reward memories contribute to intense craving and often trigger relapse. A number of interventions on drug-associated memories have shown significant benefits in relapse prevention. Among them are pre- or post-extinction pharmacological manipulations that facilitate the extinction of drug-associated behavior. Berberine, a bioactive isoquinoline alkaloid, has been recently reported to provide therapeutic benefits for a number of central nervous system (CNS) disorders, including morphine addiction. The present study aimed to investigate whether berberine could serve as a post-extinction pharmacological intervention agent to reduce risks of reinstatement of drug seeking. We found that an intragastric administration of berberine at doses of 25 and 50 mg/kg during the critical time window significantly facilitated the extinction of morphine-reward related behavior in free access and confined conditioned place preference (CPP) extinction paradigms, and subsequently, it prevented reinstatement and spontaneous recovery of morphine-induced CPP in mice. Intriguingly, the berberine treatment with or without extinction training altered expression of plasticity-related proteins such as brain-derived neurotrophic factor (BDNF), AMPA receptors (GluA1 and GluA2) in the nucleus accumbens (NAc). Moreover, the post-extinction berberine treatment significantly reduced reinstatement of cocaine-induced CPP and operant intravenous self-administration (IVSA) memories in rats. Altogether, our findings suggest that extinction training combined with the post-extinction berberine treatment can facilitate extinction of drug-associated behavior making it an attractive therapeutic candidate in relapse prevention.
Identifiants
pubmed: 32390837
doi: 10.3389/fphar.2020.00476
pmc: PMC7194034
doi:
Types de publication
Journal Article
Langues
eng
Pagination
476Informations de copyright
Copyright © 2020 Shen, Hui, Luo, Yu, Feng, Xie, Bi, Galaj, Cong, Ma and Wen.
Références
Neurotoxicology. 2016 Dec;57:241-250
pubmed: 27746125
Psychopharmacology (Berl). 2019 Feb;236(2):641-655
pubmed: 30377748
Yao Xue Xue Bao. 1962 Mar;9:145-50
pubmed: 14073958
Neuropharmacology. 2014 Jan;76 Pt B:528-32
pubmed: 23774135
Eur J Pharmacol. 2008 Jul 28;589(1-3):163-72
pubmed: 18585703
Curr Opin Neurobiol. 2013 Aug;23(4):573-80
pubmed: 23415831
Front Microbiol. 2017 Aug 25;8:1620
pubmed: 28890714
Mol Neurobiol. 2005 Oct;32(2):123-32
pubmed: 16215277
Neurosci Biobehav Rev. 2012 Apr;36(4):1119-39
pubmed: 22285426
Sci Rep. 2016 Oct 18;6:35455
pubmed: 27752130
Indian J Ophthalmol. 1982 Mar;30(2):69-75
pubmed: 6754599
Eur J Neurosci. 2019 Aug;50(3):2503-2512
pubmed: 30113098
Nat Rev Neurosci. 2011 Oct 05;12(11):685-700
pubmed: 21971065
Neuroscience. 2006 Nov 3;142(4):953-61
pubmed: 16934942
Nat Commun. 2014 Nov 25;5:5493
pubmed: 25423280
J Neurosci. 2014 May 7;34(19):6647-58
pubmed: 24806690
Avicenna J Phytomed. 2016 Mar-Apr;6(2):198-204
pubmed: 27222833
Curr Neuropharmacol. 2010 Dec;8(4):394-408
pubmed: 21629446
J Neurosci. 2010 Aug 4;30(31):10526-33
pubmed: 20685995
Phytother Res. 2010 Mar;24(3):317-24
pubmed: 19998323
BMC Complement Altern Med. 2019 May 23;19(1):109
pubmed: 31122236
Psychopharmacology (Berl). 2018 Mar;235(3):815-827
pubmed: 29250738
Psychopharmacology (Berl). 2012 May;221(1):19-26
pubmed: 22048130
Learn Mem. 2017 Jul 17;24(8):375-380
pubmed: 28716957
Behav Brain Res. 2011 Mar 1;217(2):454-62
pubmed: 21073904
Addict Behav. 1990;15(4):395-9
pubmed: 2248112
Eur J Neurosci. 2012 Mar;35(6):932-9
pubmed: 22394056
Am J Dis Child. 1975 Jul;129(7):866
pubmed: 1096596
Behav Brain Res. 2000 Oct;115(1):39-47
pubmed: 10996406
Addiction. 2019 Nov;114(11):1911-1914
pubmed: 31081567
Neuron. 2004 Sep 30;44(1):161-79
pubmed: 15450168
J Indian Med Assoc. 1967 Jan 1;48(1):1-11
pubmed: 6040104
Front Psychiatry. 2013 May 30;4:46
pubmed: 23750137
Nat Commun. 2015 Jul 14;6:7675
pubmed: 26169171
Neurochem Res. 2018 Sep;43(9):1814-1825
pubmed: 30027364
Psychopharmacology (Berl). 2019 Jan;236(1):415-437
pubmed: 30255379
Pharmacol Res. 2019 Apr;142:176-191
pubmed: 30818043
Brain Res. 2015 Dec 2;1628(Pt A):68-81
pubmed: 25451116
Oxid Med Cell Longev. 2019 May 2;2019:7593608
pubmed: 31191803
Biomed Pharmacother. 2018 Jul;103:1002-1011
pubmed: 29710498
Neuropsychiatr Dis Treat. 2013;9:1499-512
pubmed: 24109187
Nature. 2003 Jan 2;421(6918):70-5
pubmed: 12511956
Psychopharmacology (Berl). 2019 Jan;236(1):463-477
pubmed: 30392133
Annu Rev Psychol. 2004;55:51-86
pubmed: 14744210
High Blood Press Cardiovasc Prev. 2015 Jun;22(2):149-54
pubmed: 25870124
Pharmaceuticals (Basel). 2013 Dec 30;7(1):29-45
pubmed: 24380895
Brain Res Bull. 1993;30(5-6):695-700
pubmed: 8457916
Am J Drug Alcohol Abuse. 2010 Sep;36(5):233-41
pubmed: 20560821
Behav Brain Res. 2007 Dec 28;185(2):119-28
pubmed: 17826849
FASEB J. 2019 Nov;33(11):12311-12323
pubmed: 31425655
Addict Biol. 2017 Jan;22(1):3-43
pubmed: 26687226
Behav Brain Res. 2010 Mar 5;207(2):353-9
pubmed: 19840820
Science. 2012 Apr 13;336(6078):241-5
pubmed: 22499948
J Control Release. 2017 Feb 10;247:127-133
pubmed: 28065862
J Neurosci. 2017 Nov 8;37(45):10867-10876
pubmed: 29118216
Psychopharmacology (Berl). 2019 May;236(5):1513-1530
pubmed: 30982128
Front Pharmacol. 2018 May 31;9:571
pubmed: 29904348
J Neurosci. 2010 Nov 10;30(45):14993-7
pubmed: 21068303
Korean J Physiol Pharmacol. 2012 Dec;16(6):379-86
pubmed: 23269899
Addict Behav. 2003 Jul;28(5):989-94
pubmed: 12788271
Biol Psychiatry. 2008 Feb 1;63(3):338-40
pubmed: 17719565